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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.04.001INTRODUCTION: This practice survey is conducted to analyze clinical hematopoietic stem cell transplanta-
tion (HSCT) practice variability among centers in the WHO Eastern Mediterranean Region (EMRO), as repre-
sented by the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group.
METHOD: This internet based survey was completed by the medical program directors of the EMBMT centers;
17 centers participated. The survey collected data on various clinical aspects of HSCT practice.
RESULTS: Consistency in pre HSCT cardiac (100%), pulmonary (82%) and viral screen (100%) was observed.
Obtaining informed consent was universal. Pre-HSCT psychological assessment is practiced in 50% of the cen-
ters. All centers used single-bedded rooms with HEPA filters. Visitor policy during neutropenic phase and the
use of gowns, masks or gloves when examining patients varied among centers. MRSA/VRE screen and use of
low bacterial diet were applied in 65% and 82%, respectively. Anti-bacterial prophylaxis is employed in
58% (Auto-SCT) and 60% (Allo-SCT) of the centers. Drug choice varied (cotrimoxazole, ciprofloxacin, levoflox-
acin, piperacillin–tazobactam); 60% of the centers used penicillin prophylaxis in GVHD patients. PCP prophy-
laxis is applied in 58% (Auto-SCT) and 87% (Allo-SCT) of the centers; cotrimoxazole is usually used. Anti-viral
prophylaxis with acyclovir or, less commonly, valacyclovir is used in 70% (Auto-SCT) and 93% (Allo-SCT) of
centers. Anti-fungal prophylaxis is applied in 70% (Auto-SCT), 93% (myeloablative Allo-SCT) and 87% (reduced
intensity [RIC] Allo-SCT). Fluconazole is used in all Auto-SCT and majority of Allo-SCT recipients; few centers
used other agents (itraconazole, voriconazole, amphotericin B) in Allo-SCT. Prophylactic GCSF use varied
among centers: Auto-SCT 77%, myeloablative Allo-SCT 33%, RIC Allo-SCT 27%. Use of ursodeoxycholic acid
for venoocclusive disease (VOD) prophylaxis is variable: 60% (Allo-SCT) and 12% (Auto-SCT). Cyclosporine/
methotrexate is the most commonly used GVHD prophylaxis in myeloablative Allo-SCT (93%); heterogeneityHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
STEM CELL TRANSPLANTATION PRACTICE VARIATION original research reportwas seen in RIC SCT. Treatment of steroid refractory acute GVHD varied (ATG 53%, higher steroid dose 40%).
CMV monitoring varied between antigenemia (53%) and PCR (40%) techniques. Pre-emptive anti CMV therapy
is used in 86% of the centers, while 7% used routine CMV prophylaxis; 7% had no specific CMV management
policy.
CONCLUSION: Consistency was observed in areas of pre-SCT work up, use of single rooms, HEPA filters and
GVHD prophylaxis. Heterogeneity is observed in other practice aspects including other isolation measures, anti-
microbial prophylaxis, VOD prophylaxis, growth factor use and treatment of steroid refractory GVHD. Further
studies are needed to probe the impact of such practice variations on post-transplant outcome and to ascertain
the best clinical practice approach.Hematopoietic stem cell transplantation(HSCT) is a therapeutic intervention pro-vided by medical teams to patients who
usually have serious medical disorders and it carries
a potential for signiﬁcant morbidity and mortality
risks. Guidelines derived from randomized trials are
available to guide practice approach in some aspects
of HSCT, such as anti-microbial prophylaxis and
growth factor use.1–3 Conversely, other HSCT prac-
tice aspects such as isolation measures and therapy of
steroid refractory acute graft versus host disease
(GVHD) lack evidence-based guidance. Accordingly,
practice variation is anticipated among HSCT cen-
ters. Indeed, variability of practice in the ﬁeld of
HSCT has been reported in the western literature,
including variability among HSCT centers in pro-
phylaxis strategies and management of post-trans-
plant complications.4–7 Furthermore, individual
physician practice variations have also been
reported.8,9 A potential advantage of studying prac-
tice variability is identiﬁcation of areas where dissem-
ination of information and quality improvement
systems may help improve patient care in HSCT
centers.
The Eastern Mediterranean Blood and Marrow
Transplantation (EMBMT) group was established
relatively recently and covers HSCT activity in
WHO Eastern Mediterranean Region (EMRO). Lo-
cal resources and socioeconomic factors may be differ-
ent from Western countries, and therefore one may
hypothesize variation in practice in comparison to
the West. Indeed, a number of factors identiﬁed as
special issues related to HSCT centers in EMBMT
region have been identiﬁed, including type of donor
available, high prevalence of viral sero-positivity for
CMV and viral hepatitis, and low HSCT team den-
sity in comparison to Western HSCT centers.10
There are no reports on HSCT clinical routine prac-
tice within the EMRO region. This EMBMT practice
survey is conducted with the aim of analyzing clinicalHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comHSCT practice variability among centers in the
EMBMT EMRO region.METHODS
This was an internet based survey. It was com-
pleted by the medical program directors involved
in HSCT clinical practice at any of the EMBMT
centers. Each medical HSCT program director
completed one survey questionnaire only. Practitio-
ners involved in autologous SCT only may answer
questions applicable to their ﬁeld of practice and
leave questions related speciﬁcally to allogeneic
SCT practice blank.
The survey contained 16 items and took approx-
imately 15–20 min to complete. The ﬁrst 4 items
collected information on transplant center and phy-
sician characteristics. Two items collected informa-
tion about isolation practices and pre HSCT
work up in SCT centers. Six items asked questions
about the practice of anti-microbial prophylaxis and
growth factor use in each SCT center. GVHD pro-
phylaxis and treatment were assessed by 2 items.
Two questions covered VOD prophylaxis and
CMV management strategies. The concepts of this
survey were discussed and approved by the
EMBMT members during the annual EMBMT
meeting in 2011. A copy of the survey may be ob-
tained from the corresponding author.RESULTS
HSCT center characteristics
Responses from 17 HSCT centers in 10 countries
were received. These countries were Algeria, Egypt,
Iran, Jordan, Lebanon, Morocco, Oman, Pakistan,
Saudi Arabia and Tunisia. Sixty-ﬁve percent of
these centers were academic institutions, while
35% were considered both academic and community15
Figure 1. Practice specialty in EMBMT centers.
Figure 2. Number of SCT performed per year in EMBMT centers.
Figure 3. Pre-HSCT routi
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35% performed adult transplants only, 18% pediat-
ric only and 47% performed both adult and pediat-
ric transplants (Figure 1). Faculty number within
each transplant center varied widely: 59% had 3–5
faculties per center, 17% had 3 faculties, 12% 6–8
faculties and 12% had 2 faculties. The average
number of transplants performed ranged between
10–24 per year, and >100 per year (Figure 2).
Most institutions (88%) performed both allogeneic
and autologous HSCT, while 12% performed autol-
ogous HSCT only.ne work up performed prior to HSCT in EMBMT centers. LVEF: left ventric
HePre-SCT work up
Consistency in cardiac function assessment (100%) was
seen, with all institutions reporting the implementation
of formal left ventricular function assessment prior to
HSCT. Majority of centers (82%) reported obtaining
routine pulmonary function test as part of pre-trans-
plant work up. Viral screen for hepatitis B and C and
HIV was universal in all centers (100%). Similarly,
obtaining informed consent was reported by all centers.
Routine psychological assessment prior to SCT was
practiced in only 50% of the centers (Figure 3). Centre
specialty (adult vs. pediatric) was not clearly associated
with any trend toward referring transplant recipients
for psychological assessment pre-transplant. Similarly,
no association was observed between psychological
assessment and academic vs. academic/community
based institutions.
Isolation practice
Variation in isolation practice strategies in EMBMT
centers is summarized in Table 1. All centers used
single bedded rooms with HEPA ﬁlters. Routine
MRSA/VRE screen and use of low bacterial diet
were applied in 65% and 82%, respectively. Use of
gowns, masks or gloves when examining patients var-
ied signiﬁcantly between centers. Visitor policy during
neutropenic phase varied among different centers:
visiting was not allowed in 35% of the centers and re-
stricted to 2 visitors at a time in 41% of the centers,
while 24% of the centers reported other strategies.
Anti-microbial and growth factor prophylaxis
Routine anti-bacterial prophylaxis is applied in 58%
(autologous HSCT) and 60% (allogeneic HSCT) of
the centers. Signiﬁcant heterogeneity was observed
among centers with anti-bacterial drug used (choices
included cotrimoxazole, ciproﬂoxacin, levoﬂoxacinular ejection fraction; PFT: pulmonary function test.
matol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.com
Table 1. Summary of variation in isolation practice strategies in
EMBMT centers.
Isolation practice measure Yes (%) No (%)
Single bedded room 100 –
HEPA filter 100 –
Use of masks 81 19
Gloves when examining patients 53 47
Gowns when examining patients 70 30
Hand washing between patients 100 –
Routine MRSA/VRE screen 65 35
Use of low bacterial diet 82 18
Figure 4. CMV management strategies in allogeneic SCT in EMBMT
centers.
STEM CELL TRANSPLANTATION PRACTICE VARIATION original research reportand piperacillin–tazobactam). In patients with
GVHD, routine penicillin prophylaxis is used in
60% of the centers.
PCP prophylaxis is used in 58% (autologous SCT)
and 87% (allogeneic SCT) of the centers. Among
these centers, cotrimoxazole was universally used.
Routine anti-viral prophylaxis is used in 70% (autolo-
gous SCT) and 93% (allogeneic SCT) of the centers,
with acyclovir being the most commonly used agent
and valacyclovir being used by few centers.
Anti-fungal prophylaxis in autologous SCT is ap-
plied in 70% of the centers, with ﬂuconazole being
universally used in these centers. In allogeneic SCT,
anti-fungal prophylaxis is utilized in 93% (myeloabla-
tive SCT) and 87% (reduced intensity) of the centers;
ﬂuconazole was the most commonly used agent, while
few centers reported using other antifungal agents
(itraconazole, voriconazole and amphotericin B).
In autologous SCT patients G-CSF is routinely
recommended (in the absence of febrile neutropenia
or documented infection) in 77% of the centers. In
allogeneic SCT recipients, prophylactic G-CSF is rec-
ommended in 33% (myeloablative SCT) and 27% (re-
duced intensity SCT) of the centers.
Veno-occlusive disease (VOD) prophylaxis
For autologous SCT, most centers (88%) reported
not using ursodeoxycholic acid for VOD prophylaxis.
In the allogeneic setting, routine use of ursodeoxy-
cholic acid for VOD prophylaxis was reported in
60% of the centers (both in the myeloablative and re-
duced intensity SCT settings). There was no clear
association between use of VOD prophylaxis and
center specialty (adult vs. pediatric). Centers reported
as purely academic were more likely to report usingHematol Oncol Stem Cell Ther 6(1) First Quarter 2013 hemoncstem.edmgr.comursodeoxycholic acid VOD prophylaxis than centers
reported as being both academic/community-based.
GVHD prophylaxis and therapy
Cyclosporine/methotrexate was the most commonly
reported GVHD prophylactic regimen in myeloabla-
tive allogeneic SCT setting (93%). Greater heteroge-
neity between centers was seen in reduced intensity
allogeneic SCT: 39% reported using cyclosporine/
methotrexate, 46% cyclosporine/mycophenolate and
15% other regimens. Treatment of steroid refractory
acute GVHD varied between using ATG (53%) or
higher steroid doses (40%). Among centers using
ATG for this indication, Rabbit ATG was reported
to be used in majority of cases.
CMV management strategies in allogeneic HSCT
CMV monitoring varied among centers between the
use of antigenemia (53%) and PCR (40%) techniques.
Pre-emptive anti CMV therapy is applied in the
majority (87%) of the centers, while 7% used routine
CMV prophylaxis and 7% had no speciﬁc routine
CMV management policy. Summary of CMV man-
agement strategy is illustrated in Figure 4.DISCUSSION
The present study describes the current aspects of
HSCT practice within the EMBMT group in the
EMRO region. We found a high degree of consis-
tency in aspects of pre-transplant cardiac and pulmon-
ary function assessment as well as serology screen for
viral hepatitis and HIV viruses. This likely reﬂects the
beliefs of most transplant physicians of the impor-
tance of adequate organ function prior to HSCT.
Indeed, organ function assessment is fundamental
in recent HSCT comorbidity scores, reﬂecting
important prognostic information and sometimes
impacting on intensity of conditioning regimen used
in selected patients.1117
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An important pre-transplant assessment tool is
mental evaluation and psychological support prior to
HSCT. Only 50% of the centers indicated they would
routinely arrange for patients to meet with a psychol-
ogist. Clearly, the support of a psychologist may alle-
viate distress and fears that many patients have prior
to undergoing this major therapeutic intervention
with potential morbidity and mortality. Furthermore,
routine psychologist interview may identify salient
depression or anxiety disorders that may require
intervention in these patients. In fact, some reports
suggest increased mortality post HSCT in patients
with pre-transplant depressive features.12,13 The rea-
son for the relatively low rate of formal mental assess-
ment prior to HSCT is not clear, but may possibly be
related to unavailability of specialized staff in these
centers.
HEPA ﬁlters and single bedded rooms were uni-
versal in all centers, reﬂecting the standard accepted
practice worldwide. In contrast, there was a signiﬁcant
heterogeneity in other isolation measures and visitor
policy during neutropenic phase, which are areas that
lack speciﬁc evidence-based guidelines.
Anti-microbial prophylaxis showed signiﬁcant het-
erogeneity among centers. This is surprising given the
availability of published evidence based guidelines in
this regard.2,3 The implementation of anti-bacterial
prophylaxis was relatively low. PCP prophylaxis was
used more commonly, yet a small percentage indicated
PCP prophylaxis is not routinely used in all patients.
Similar results pertain to anti-fungal prophylaxis. In
centers practicing PCP and anti-fungal prophylaxis,
there was in general consistency of agents used, with
cotrimoxazole and ﬂuconazole, respectively being
most commonly used.
Although prophylactic growth factor use is more
common in autologous than allogeneic HSCT, the
overall pattern is not consistent with published guide-
lines, which recommends its use in autologous, but
not allogeneic HSCT.14 Of note, there was no
correlation between pattern of GCSF and center
specialty (adult vs. pediatric). Only 60% of the centers
performing allogeneic HSCT reported the use of urso-Hedeoxycholic acid as prophylaxis for VOD. This is a
potentially lethal complication post HSCT, occurring
mainly in myeloablative allogeneic HSCT recipients
and a number of randomized clinical trials demon-
strated that ursodeoxycholic acid is effective in its pre-
vention.15–17
Reports on type of GVHD prophylaxis in
myeloablative allogeneic HSCT were consistent with
the currently most widely used regimen, namely cyclo-
sporine/ methotrexate. Types of GVHD prophylaxis
regimen reported to be used in reduced intensity set-
ting were more heterogeneous as expected, which is
similar to practice trends in Western transplant cen-
ters. CMV monitoring and management strategies
were generally consistent with current practice guide-
lines and trends, which favor pre-emptive rather than
routine prophylaxis approach.3,18
An area of potential weakness in our study is lim-
iting the survey to program directors in EMBMT cen-
ters. However, questionnaire types in this survey were
predominantly designed to answer mainly practice
policy in each HSCT based on each center’s standard
protocol; this was felt to be answered by the program
director reﬂecting on corresponding center’s HSCT
protocols. Surveys with vignette type questions
enquiring about speciﬁc clinical scenario management
would be more suitable to be answered by each indi-
vidual HSCT physician to reﬂect individual practice
variability.
Results of this brief survey should encourage
further studies of HSCT practice in the EMRO
region. In future studies, we intend to analyze individ-
ual physician variability of practices within the
EMBMT region, and reﬂect on potential factors that
may affect practice variability in this region. Our re-
sults suggest an area of potential improvement toward
more consistency in practice in ﬁelds where evidence
based literature and consensus guidelines are available.
In cases where such evidence is lacking, demonstra-
tion of practice variability among HSCT centers rein-
forces the need to conduct randomized trials and
observational studies in order to ascertain the best
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